RayKnowChina Research Map
Shortlist

Cancer

Breast cancer in Nanjing

南京 乳腺癌

All diseases in Nanjing

6 hospitals in Nanjing

Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Nanjing may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 250 papers led
  2. 47 papers led
  3. 45 papers led
    No open trial led
  4. 24 papers led
    No open trial led
  5. 19 papers led
    No open trial led
  6. 0 papers led
    No open trial led

Breast cancer in every city Nanjing on the disease page, with the national map

64

open trials on breast cancer with a hospital in Nanjing

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Nanjing as lead sponsor or study site. 26 of them are led by a hospital in Nanjing. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07281976

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Guangzhou, Harbin, Nanjing, Shenyang, Zhengzhou

  2. Recruiting
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07347600

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou

  3. Recruiting
    A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07349069

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  4. Recruiting
    Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07396454

    Age 18 years to 70 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  5. Recruiting
    RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07413939

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan

  6. Recruiting
    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07492641

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

  7. Recruiting
    Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07498478

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan

  8. Recruiting
    QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07601178

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  9. Recruiting
    Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07616427

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou, Nanjing

  10. Recruiting
    A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07622836

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  11. Recruiting
    Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07698366

    Age 65 years to 80 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  12. Recruiting
    SMP-656 for HER2-Positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07726342

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou

  13. Recruiting
    A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07743944

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  14. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07876557

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou

  15. Recruiting
    A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07900516

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  16. Recruiting
    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06757634

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shenyang, Tianjin, Weifang, Xi'an, Xinxiang, Yangzhou, Zhengzhou

  17. Recruiting
    To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort)
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06817954

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  18. Recruiting
    Hypofractionated Radiation Fractionation in Breast Cancer Patients With Implant-Based Reconstruction
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06830083

    Age 18 years to 65 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  19. Recruiting
    A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06830889

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  20. Recruiting
    A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06841354

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  21. Recruiting
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06966700

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou

  22. Recruiting
    A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07003074

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Hefei, Jinan, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Urumqi, Wuhan

  23. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  24. Recruiting
    JS207 Combination Therapy in Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07045311

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou

  25. Recruiting
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07047365

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou

  26. Recruiting
    A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07060807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou

  27. Recruiting
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07062965

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an

  28. Recruiting
    Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT07113613

    Age 30 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  29. Recruiting
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07169994

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang

  30. Recruiting
    An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07222267

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Xiamen

  31. Recruiting
    Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07263425

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  32. Recruiting
    Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT07394387

    Age 18 years to 70 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  33. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  34. Recruiting
    The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06254690

    Age 18 years to 70 years; women only (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  35. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  36. Recruiting
    Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06543992

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  37. Recruiting
    The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
    Phase
    Phase 1
    Started
    2024-11
    Posted
    Registry
    NCT06770296

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  38. Recruiting
    Effect of Subanesthetic Dose of Esketamine on Sleep Quality
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06773143

    Age 18 years to 65 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  39. Recruiting
    RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT07065435

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  40. Recruiting
    Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT07446452

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  41. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05646862

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan

  42. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  43. Recruiting
    Pyrotinib in Women With High-risk in Early Stage Breast Cancer
    Phase
    Phase 2
    Started
    2023-04
    Posted
    Registry
    NCT05834764

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  44. Recruiting
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05860465

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan

  45. Recruiting
    Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT05872347

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou

  46. Recruiting
    Omission of SLNB in CN0 Early Breast Cancer
    Phase
    N/A
    Started
    2023-06
    Posted
    Registry
    NCT05935150

    Age 18 years to 70 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  47. Recruiting
    Omission of ALND in Breast Cancer Patients With Axillary pCR
    Phase
    N/A
    Started
    2023-09
    Posted
    Registry
    NCT05939830

    Age 18 years to 70 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  48. Recruiting
    A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06001086

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  49. Recruiting
    A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
    Phase
    Phase 1/Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06064812

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  50. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  51. Recruiting
    Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06341894

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  52. Recruiting
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05851014

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou

  53. Recruiting
    Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
    Phase
    Not given
    Started
    2022-10
    Posted
    Registry
    NCT06551220

    Age 18 years to 80 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai

  54. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

  55. Not yet recruiting
    Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07481903

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesBeijing, Nanjing, Tianjin

  56. Not yet recruiting
    Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07523789

    Age 18 years to Not stated; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  57. Not yet recruiting
    Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07745257

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 8 listed hospitals as study sitesAnyang, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Nanjing, Shijiazhuang, Zhengzhou

  58. Not yet recruiting
    A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07782086

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hefei, Luzhou, Nanjing, Shanghai, Xi'an, Xuzhou

  59. Not yet recruiting
    QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07113964

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  60. Not yet recruiting
    Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT06234150

    Age 18 years to 65 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  61. Not yet recruiting
    To Evaluate the Effectiveness and Safety of the Single-port Robotic-assisted Breast Surgery in Breast Cancer
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06561646

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  62. Not yet recruiting
    Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
    Phase
    N/A
    Started
    2022-08
    Posted
    Registry
    NCT05460819

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  63. Not yet recruiting
    Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
    Phase
    N/A
    Started
    2022-12
    Posted
    Registry
    NCT05613504

    Age 30 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  64. Enrolling by invitation
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07376629

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Nanjing

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Nanjing, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated BenQ Hospital of Nanjing Medical University南京明基医院nonenonenonenonenonenonenonenonenonenonenone1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Brain Hospital of Nanjing Medical University南京脑科医院nonenonenonenone45nonenone21nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenone2nonenonenonenonenone5nonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Eye Hospital of Nanjing Medical University南京医科大学眼科医院nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hospital of Nanjing University南京大学医学院附属鼓楼医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hospital of Nanjing University of Chinese Medicine南京中医药大学附属医院nonenonenone21none18nonenonenonenonenone20nonenonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenone6nonenonenonenonenone3nonenonenonenonenonenonenonenone1nonenonenone1nonenonenonenonenonenonenonenonenonenone
Affiliated Hospital, Nanjing Medical University南京医科大学附属口腔医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone
Affiliated Hospital, Nanjing University of Chinese Medicine江苏省中西医结合医院nonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hospital, Nanjing University of Traditional Chinese Medicine江苏省中医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenone1nonenonenonenonenonenonenonenonenonenone
Affiliated Jiangning Hospital, Nanjing Medical University南京市江宁医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Jiangsu Shengze Hospital of Nanjing Medical University江苏盛泽医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Lianyungang Hospital of Xuzhou Medical University连云港市第一人民医院nonenonenonenonenonenonenonenonenonenonenonenonenone2none4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated People's Hospital of Jiangsu University江苏大学附属人民医院nonenonenone21nonenonenonenonenonenonenone1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Yancheng Hospital, Southeast University盐城市第三人民医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children's Hospital of Nanjing Medical University南京市儿童医院nonenonenonenonenonenonenonenone3nonenone1none151 opennonenone1nonenonenonenone0nonenonenonenonenonenonenonenone9none23none1nonenone0nonenonenone0none02010nonenonenonenonenone9nonenone0nonenonenonenone
Fourth Affiliated Hospital of Nanjing Medical University南京医科大学第四附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Gaochun People's Hospital南京市高淳人民医院nonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiangsu Cancer Hospital江苏省肿瘤医院141 open252 open16261233 open6471 open15nonenonenone00nonenonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenone
JiangSu Provincce Hospital江苏省人民医院nonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiangsu Province Hospital江苏省人民医院(南医大一附院)11368 open1175 open19923 open2335 open914 open25025 open59none014141 open82 open0246 open01 open9228119 open10nonenonenonenonenone433 opennonenone10115 open18nonenone2none10none4none1none10none21none101none00021nonenonenone
Jiangsu Provincial People's Hospital江苏省人民医院(南京医科大学第一附属医院)nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiangyin Hospital, Nanjing University of Chinese Medicine江阴市中医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jinling Hospital东部战区总医院(金陵医院)none9231 open201 open76113 open1924none0none140nonenone41 opennonenonenone5nonenone01nonenone01 opennonenonenonenone242 open2nonenonenonenone2none2nonenonenonenonenone510nonenone0nonenonenone00none1nonenonenonenone
Nanjing Bayi Hospital中国人民解放军第八一医院nonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Chest Hospitalnonenonenonenone25nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Drum Tower Hospital南京鼓楼医院213952 open1133 open811 open635 open4518nonenonenone8121none17nonenonenone20none2nonenonenone0none27nonenone121 open8821 opennone1none31none0none0nonenone0none3nonenone011nonenone01nonenonenonenonenone
Nanjing Drum Town Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing First Hospital南京市第一医院nonenonenonenonenonenonenonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Jiangbei Hospital南京江北医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Pukou District Hospital南京市浦口人民医院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Second Hospital南京市第二医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenone30nonenonenonenonenonenonenonenonenone
Nanjing Stomatological Hospital南京市口腔医院nonenonenonenonenonenonenonenonenonenonenone0nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Tianyinshan Hospital南京天印山医院nonenone11 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Nanjing Medical University南京医科大学第二附属医院0none191 open122361 opennonenonenonenone1321nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenone8nonenonenonenone11none1nonenonenonenone1none1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Hospital, Nanjing University of Chinese Medicine江苏省第二中医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenone
Shuyang Hospital, Nanjing University of Chinese Medicine沭阳县中医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Sir Run Run Hospital南京医科大学附属逸夫医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Third Affiliated Hospital of Nanjing University of Chinese Medicine南京市中医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenone16nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Women's Hospital, Nanjing Medical University南京市妇幼保健院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenone1none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yancheng First Hospital, Nanjing University盐城市第一人民医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yancheng TCM Hospital, Nanjing University of Chinese Medicine盐城市中医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Zhongda Hospital, Southeast University东南大学附属中大医院none18599 open211 open47222412none10312240nonenone7nonenonenone1nonenonenonenonenonenonenone3432nonenonenone1none1none0nonenonenonenone3nonenonenone1none1nonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Nanjing.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for breast cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Nanjing on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data